Addendum
Romosozumab (osteoporosis) - Addendum to Commission A20-24
Report documents
-
Addendum
Romosozumab (osteoporosis) - Addendum to Commission A20-24
Dossier assessment
Indication:
| Postmenopausal women with severe osteoporosis at high risk of fracture |
Result of dossier assessment:
| Negative effect for the outcome "cerebrovascular event" qualifies positive effects; now indication of minor added benefit. |
Additional information
Federal Joint Committee (G-BA)
03.09.2020 A G-BA decision was published.
Project details
- Project no.
- A20-67
- Commission
- Commission awarded on 28.07.2020 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Muscles, bones and joints
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Romosozumab (osteoporosis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed